Krystal Biotech Q3 EPS Forecast Decreased by William Blair

Key Points

• William Blair has revised down its Q3 2025 EPS forecast for Krystal Biotech from $1.38 to $1.14, while the full-year earnings consensus stands at $6.14 per share.
• Despite the EPS revision, Krystal Biotech reported a Q2 2025 EPS of $1.29, surpassing analyst expectations of $1.08 and achieving $96.04 million in revenue.
• Institutional interest in Krystal Biotech is strong, with 86.29% of the stock owned by institutional investors, and notable increases in holdings from firms like Mitsubishi UFJ Asset Management and Aviva PLC.

Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - Equities researchers at William Blair cut their Q3 2025 earnings estimates for Krystal Biotech in a research note issued to investors on Monday, August 4th. William Blair analyst S. Corwin now expects that the company will earn $1.14 per share for the quarter, down from their previous estimate of $1.38. The consensus estimate for Krystal Biotech's current full-year earnings is $6.14 per share. William Blair also issued estimates for Krystal Biotech's Q1 2026 earnings at $1.40 EPS, Q2 2026 earnings at $1.88 EPS, Q3 2026 earnings at $2.16 EPS, Q4 2026 earnings at $2.93 EPS and FY2026 earnings at $8.37 EPS.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The company reported $1.29 EPS for the quarter, beating analysts' consensus estimates of $1.08 by $0.21. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%. The business had revenue of $96.04 million for the quarter, compared to analysts' expectations of $95.42 million.

Other analysts have also issued research reports about the company. Chardan Capital reissued a "buy" rating and set a $219.00 price objective on shares of Krystal Biotech in a research note on Tuesday. HC Wainwright reissued a "buy" rating and set a $240.00 price objective on shares of Krystal Biotech in a research note on Friday, July 25th. Guggenheim dropped their price objective on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Citigroup reaffirmed a "neutral" rating and issued a $166.00 price target (down previously from $176.00) on shares of Krystal Biotech in a research note on Tuesday. Finally, Bank of America dropped their price target on Krystal Biotech from $193.00 to $192.00 and set a "buy" rating for the company in a research note on Tuesday, July 22nd. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $210.22.

Krystal Biotech Price Performance

Shares of NASDAQ KRYS opened at $136.00 on Thursday. The stock has a market capitalization of $3.93 billion, a P/E ratio of 27.64 and a beta of 0.70. Krystal Biotech has a one year low of $122.80 and a one year high of $207.84. The firm's 50 day simple moving average is $141.24 and its two-hundred day simple moving average is $155.67.

Hedge Funds Weigh In On Krystal Biotech

Several institutional investors and hedge funds have recently modified their holdings of the stock. Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in shares of Krystal Biotech by 20.3% during the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 1,795 shares of the company's stock valued at $247,000 after acquiring an additional 303 shares in the last quarter. Aviva PLC increased its holdings in Krystal Biotech by 9.8% in the 2nd quarter. Aviva PLC now owns 3,575 shares of the company's stock worth $491,000 after buying an additional 319 shares in the last quarter. Los Angeles Capital Management LLC increased its holdings in Krystal Biotech by 6.9% in the 2nd quarter. Los Angeles Capital Management LLC now owns 26,638 shares of the company's stock worth $3,662,000 after buying an additional 1,709 shares in the last quarter. Resona Asset Management Co. Ltd. bought a new stake in Krystal Biotech in the 2nd quarter worth about $401,000. Finally, EFG Asset Management North America Corp. increased its holdings in Krystal Biotech by 31.7% in the 2nd quarter. EFG Asset Management North America Corp. now owns 22,878 shares of the company's stock worth $3,144,000 after buying an additional 5,507 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors.

Insider Transactions at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 13,435 shares of the stock in a transaction on Monday, July 14th. The stock was sold at an average price of $150.30, for a total value of $2,019,280.50. Following the completion of the transaction, the insider owned 1,443,276 shares in the company, valued at approximately $216,924,382.80. This represents a 0.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 49,800 shares of company stock valued at $7,487,943 in the last ninety days. 13.70% of the stock is currently owned by corporate insiders.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.